<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Celgene Corp. | Company News & Executive Profiles - CELG | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/celgene+corp..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Celgene Corp.]]></description>
	<s:counts start="0" returned="10" found="214" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Celgene: Buy on a Pullback]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F171182-celgene-buy-on-a-pullback%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ockham Research submits:  &#8220;So why do we like Celgene so much, and how come we have time? The main reason I like it is its huge blood cancer drug Revlimid. $1.3 billion sales in 2008. It&#8217;s approved by the FDA to treat multiple myeloma. That&#8217;s a cancer of the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 04 Nov 2009 09:09:36 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/ockham+research.html"><![CDATA[Ockham Research]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Celgene Corporation Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-355423.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. Operator instructions And we will take our first question from Maged Shenouda with UBS. Maged Shenouda &#8211; UBS Hi. Thanks for taking my question. Can you outline your plans for top line growth over the next few years as we wait for execution on your...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 22 Oct 2009 11:43:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/japan.html"><![CDATA[Japan]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Earnings Preview: Celgene]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F167900-earnings-preview-celgene%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Celgene CELG is expected to report Q3 earnings  Thursday, October 22 before market open, with a conference call scheduled for  9:00 am ET.  Guidance Analysts are looking for EPS of 54c on revenue of $671.89M. The  consensus range is 52c-59c for EPS, and $656M-$691M for revenue,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 21 Oct 2009 10:50:08 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/theflyonthewall.com.html"><![CDATA[theflyonthewall.com]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Celgene to Widow Who Discovered Thalomid: Go Take a Running Jump]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003908/celgene-to-widow-who-discovered-thalomid-go-take-a-running-jump/]]></link>
		<description><![CDATA[Celgene thanked the woman who had the idea to use thalidomide as a treatment for multiple myeloma in its annual report, but says she isn't owed a dime for discovering the $2.2 billion-a-year treatment. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 26 Aug 2009 09:21:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Lawyer Says Drugmaker Celgene Stole Her Idea]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/news-analysis/lawyer-drugmaker-celgene-stole-idea/9281/]]></link>
		<description><![CDATA[In 1996, Beth Jacobson was watching her husband, a 35-year-old cardiologist, die from the blood cancer multiple myeloma. She spent her nights reading medical journals at his bedside and her days calling doctors. One Saturday night, Judah Folkman, the famed Harvard cancer researcher, returned her call, and they came up...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 26 Aug 2009 07:55:12 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/idea.html"><![CDATA[idea]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Celgene Corp.: Why This Biotech Drugmaker Is Turning Heads]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F152373-celgene-corp-why-this-biotech-drugmaker-is-turning-heads%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Invest With An Edge submits:  By Brandon Clay Some sectors tend to do better than others in tough times.  Healthcare is one such area.  Moreover, the biotechnology sub-sector often surprises investors in good times and bad.  This sometimes-perilous niche can make or break a portfolio depending...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 30 Jul 2009 12:35:47 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/invest+with+an+edge.html"><![CDATA[Invest With An Edge]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Celgene Corporation Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F150926-celgene-corporation-q2-2009-earnings-call-transcript%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Celgene Corporation CELG   Q2 2009 Earnings Call   July 23, 2009; 9:00 am ET]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 23 Jul 2009 12:59:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Celgene Corporation Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-324037.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions Your first question comes from Jim Birchenough - Barclays Capital. Jim Birchenough - Barclays Capital Just on 015, I just want to conform that that the pre-specified interim analysis was focused on the MPR, plus maintenance versus MP, and not MPR induction alone versus MP....]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 23 Jul 2009 11:59:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/arm.html"><![CDATA[Arm]]></category>
		<category domain="http://resources.bnet.com/topic/europe.html"><![CDATA[Europe]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Earnings Preview: Celgene Corporation]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F150545-earnings-preview-celgene-corporation%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Celgene CELG is expected to report Q2 earnings Thursday, July 23 before the market open, with a conference call scheduled for 9:00 am ET.  Guidance Analysts are looking for EPS of 46c on revenue of $621M. The consensus range is 42c-49c for EPS, and $603M-$640M for revenue, according to...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 22 Jul 2009 11:37:29 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/theflyonthewall.com.html"><![CDATA[theflyonthewall.com]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Celgene: Solid Balance Sheet and Promising Pipeline]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F142176-celgene-solid-balance-sheet-and-promising-pipeline%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[I have been looking for a solid pharmaceutical company to add to my stock portfolio.  I had owned Pfizer PFE previously but Pfizer appears to be a drug company with a dearth of drugs in its pipeline.   The days of growth appear over and I am looking...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 09 Jun 2009 05:01:13 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mark+riddix.html"><![CDATA[Mark Riddix]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
</channel>
</rss>
